220 related articles for article (PubMed ID: 23832263)
1. Changes in antiplatelet use prior to incident ischaemic stroke over 7 years in a UK centre and the association with stroke subtype.
White JR; Bettencourt-Silva JH; Potter JF; Loke YK; Myint PK
Age Ageing; 2013 Sep; 42(5):594-8. PubMed ID: 23832263
[TBL] [Abstract][Full Text] [Related]
2. Secondary medical prevention after primary vascular surgery between 1996 and 2006: a shift towards more evidence-based treatment.
Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
Eur J Prev Cardiol; 2013 Oct; 20(5):763-70. PubMed ID: 22637739
[TBL] [Abstract][Full Text] [Related]
3. Impact of the additive effect of angiotensin-converting enzyme inhibitors and /or statins with antiplatelet medication on mortality after acute ischaemic stroke.
Hassan Y; Al-Jabi SW; Aziz NA; Looi I; Zyoud SH
Basic Clin Pharmacol Toxicol; 2012 Apr; 110(4):370-7. PubMed ID: 22023326
[TBL] [Abstract][Full Text] [Related]
4. Ischemic stroke in patients receiving aspirin.
Pujol Lereis VA; Ameriso S; Povedano GP; Ameriso SF
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):868-72. PubMed ID: 21703876
[TBL] [Abstract][Full Text] [Related]
5. Long-term adherence to national guidelines for secondary prevention of ischemic stroke: a prospective cohort study in a public hospital in Chile.
Muñoz-Venturelli P; Sacks C; Madrid E; Lavados PM
J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):490-5. PubMed ID: 23680688
[TBL] [Abstract][Full Text] [Related]
6. Evaluation on the compliance with secondary prevention and influence factors of ischemic stroke in Hainan province, China.
Su Q; Yuan K; Long F; Wan Z; Li C; Cai Y; Zeng C; Wu Y; Wu H; Liu S; Li P; Zhou J; Chen C; Wang D; Yan L; Zhang Y; Dai M
Vascular; 2014 Jun; 22(3):181-7. PubMed ID: 23929417
[TBL] [Abstract][Full Text] [Related]
7. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
8. Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke.
Kim D; Lee SH; Joon Kim B; Jung KH; Yu KH; Lee BC; Roh JK;
Eur Heart J; 2013 Sep; 34(35):2760-7. PubMed ID: 23729692
[TBL] [Abstract][Full Text] [Related]
9. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study.
Ostergaard K; Pottegård A; Hallas J; Bak S; dePont Christensen R; Gaist D
Neuroepidemiology; 2014; 43(1):57-64. PubMed ID: 25323533
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland.
Bednarski J; Cieszewska E; Strzelecki A; Filipiak KJ
Kardiol Pol; 2013; 71(12):1260-5. PubMed ID: 23990227
[TBL] [Abstract][Full Text] [Related]
12. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register.
Asberg S; Henriksson KM; Farahmand B; Asplund K; Norrving B; Appelros P; Stegmayr B; Asberg KH; Terént A
Stroke; 2010 Jul; 41(7):1338-42. PubMed ID: 20522818
[TBL] [Abstract][Full Text] [Related]
13. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Burke JP; Sander S; Shah H; Zarotsky V; Henk H
Curr Med Res Opin; 2010 May; 26(5):1023-30. PubMed ID: 20199138
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy in the prevention of ischaemic stroke.
Verry M; Panak E; Cazenave JP
Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy prior to and in acute ischaemic stroke. The use of pharmacotherapy and drug-associated outcomes in real world practice - findings from the Polish Hospital Stroke Registry.
Niewada M; Sarzyńska-Długosz IM; Skowrońska M; Kamiński B; Kobayashi A; Członkowska A
Neurol Neurochir Pol; 2013; 47(6):509-16. PubMed ID: 24374995
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet drugs for ischemic stroke prevention.
Leys D; Balucani C; Cordonnier C
Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Lee MS; Smith SD; Galor A; Hoffman GS
Arthritis Rheum; 2006 Oct; 54(10):3306-9. PubMed ID: 17009265
[TBL] [Abstract][Full Text] [Related]
18. Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation.
Yu HC; Tsai YF; Chen MC; Yeh CH
Int J Stroke; 2012 Feb; 7(2):112-7. PubMed ID: 22103748
[TBL] [Abstract][Full Text] [Related]
19. Hemorrhage after ischemic stroke - relation to age and previous hemorrhage in a nationwide cohort of 58,868 patients.
Åsberg S; Henriksson KM; Farahmand B; Terént A
Int J Stroke; 2013 Feb; 8(2):80-6. PubMed ID: 22168375
[TBL] [Abstract][Full Text] [Related]
20. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey.
Heuschmann PU; Kircher J; Nowe T; Dittrich R; Reiner Z; Cifkova R; Malojcic B; Mayer O; Bruthans J; Wloch-Kopec D; Prugger C; Heidrich J; Keil U
Eur J Prev Cardiol; 2015 Oct; 22(10):1354-62. PubMed ID: 25139770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
